Pilot Study of Using Copeptin to Predict Response to Tolvaptan

Completed · Phase 4

Conditions studied: Cardiovascular Diseases, Heart Diseases, Heart Failure

In brief

This pilot study will investigate the association between levels of the peptide copeptin and response to tolvaptan, a drug that blocks the action of the water retaining hormone vasopressin. The study will enroll stable outpatients with CHF with reduced LVEF (≤45) selected by targeting upper and lower quartile copeptin levels at screening (10 each). The treatment phase of the study will be a prospective, single-arm, open label protocol. All patients will receive active therapy consisting of a single oral dose of 30 mg of tolvaptan with body weight, fluid intake, and urine output monitored in a research unit for 24 hours. For analysis of study endpoints, patients in the single intervention arm will be stratified by a prospectively determined cut-point of copeptin level into two groups (≥10 versus \<10 pmol/L). The copeptin level used for the two group stratification will be the blinded copeptin value obtained at baseline from the hospital phase prior to administration of tolvaptan.

Key facts

Study ID

NCT01346072

Run by

University of North Carolina, Chapel Hill

People needed

21

Starts

2011-04-01

Expected to finish

2014-12-01

Last updated by the study team

2017-05-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female patients with a history of chronic symptomatic heart failure, defined as dyspnea on exertion or edema, due to cardiac dysfunction, of at least one month's duration
• Left ventricular ejection fraction ≤ 45% as documented by quantitative assessment by an accepted imaging technique within one year of screening
• Meet baseline copeptin criteria for entry
• Currently taking a diuretic (with diuretic defined as any loop or thiazide diuretic or aldosterone antagonist at any dose)

You may not qualify if…

• Current New York Heart Association Functional Class IV heart failure
• Patients who are felt to be volume depleted based on clinical examination or need to reduce diuretic administration
• Presence of clinical contraindications to tolvaptan
• Episode of acute myocardial infarction or acute coronary syndrome within the past 3 months
• Cardiovascular surgical procedure within the past 4 weeks
• CHF due to uncorrected thyroid disease, active myocarditis, or known amyloid cardiomyopathy.
• History of primary significant liver disease or acute hepatic failure, as defined by the investigator.
• Chronic uncontrolled diabetes mellitus as determined by the investigator.
• Supine systolic arterial blood pressure < 90 mmHg at screening
• Serum creatinine > 3.5 mg/dL at screening
• Serum potassium > 5.5 mEq/L or < 3.5 mEq/L at screening
• Subjects currently treated with hemofiltration or dialysis
• j. Subjects judged by the investigator to be unable to maintain accurate intake and output during their hospitalization related to medical or other problems

Where it is running

• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.